Environment-mediated drug resistance: A major contributor to minimal residual disease

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

Treatment of Acute Lymphoblastic Leukemia

Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,983 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

Stromal Gene Signatures in Large-B-Cell Lymphomas

Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,818 · see citing works

Stimulation of Bone Formation in Vitro and in Rodents by Statins

Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776 · see citing works

Stromal gene expression predicts clinical outcome in breast cancer

Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687 · see citing works

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638 · see citing works

Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies

Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483 · see citing works

A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer

Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380 · see citing works

DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance

DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333 · see citing works

Molecular characterization of the tumor microenvironment in breast cancer

Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299 · see citing works

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

Weitz‐Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J. A., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041 · see citing works

TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT

Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 981 · see citing works

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899 · see citing works

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo

Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D. M., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R. M., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739 · see citing works

Co-evolution of tumor cells and their microenvironment

Polyák, K., Haviv, I., & Campbell, I. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.10.012 · Cited by 622 · see citing works

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 564 · see citing works

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M. H., Mesters, R. M., Serve, H. L., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 562 · see citing works

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

Meads, M. B., Hazlehurst, L., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 519 · see citing works

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R., Ling, X., Frolova, O., Levis, M. J., Rubin, J. B., Negrin, R. S., Estey, E. H., et al. (2008) · Blood · doi:10.1182/blood-2008-05-158311 · Cited by 518 · see citing works

Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma Cells

Pantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., Funke, I., Izbicki, J. R., & Riethmüller, G. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1419 · Cited by 503 · see citing works

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

Reardon, D. A., Fink, K., Mikkelsen, T., Cloughesy, T. F., O’Neill, A., Plotkin, S. R., Glantz, M., Ravin, P. D., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 478 · see citing works

Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction

White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.025 · Cited by 413 · see citing works

Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients

Braun, S., Kentenich, C. R. M., Janni, W., Hepp, F., Waal, J. D., Willgeroth, F., Sommer, H. L., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394 · see citing works

Radiation to Stromal Fibroblasts Increases Invasiveness of Pancreatic Cancer Cells through Tumor-Stromal Interactions

Ohuchida, K., Mizumoto, K., Murakami, M., Qian, L.-W., Sato, N., Nagai, E., Matsumoto, K., Nakamura, T., & Tanaka, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2464 · Cited by 385 · see citing works

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

Kraft, A., Weindel, K., Ochs, A. G., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marm�, D., & Gastl, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1 · Cited by 370 · see citing works

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yü, P., Fu, Y., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359 · see citing works

Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)

Hazlehurst, L., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 343 · see citing works

Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Naumov, G. N., MacDonald, I. C., Weinmeister, P. M., Kerkvliet, N. I., Nadkarni, K. V., Wilson, S. M., Morris, V. L., Groom, A. C., & Chambers, A. F. (2002) · PubMed · Cited by 341 · see citing works

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells

Sherman‐Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T. L., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 340 · see citing works

Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in Vivo

Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R., Crawford, J. W., & Frei, E. (1990) · Science · doi:10.1126/science.2108497 · Cited by 327 · see citing works

β1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and <i>In vivo</i>

Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3071 · Cited by 326 · see citing works

Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

Croix, B. S., Flørenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., & Kerbel, R. S. (1996) · Nature Medicine · doi:10.1038/nm1196-1204 · Cited by 321 · see citing works

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells

Burger, M., Hartmann, T. N., Krome, M., Rawluk, J. K., Tamamura, H., Fujii, N., Kipps, T. J., & Burger, J. A. (2005) · Blood · doi:10.1182/blood-2004-12-4918 · Cited by 295 · see citing works

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells

Hartmann, T. N., Burger, J. A., Glodek, A. M., Fujii, N., & Burger, M. (2005) · Oncogene · doi:10.1038/sj.onc.1208621 · Cited by 281 · see citing works

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., & Gabrilovich, D. I. (2003) · Blood · doi:10.1182/blood-2003-07-2340 · Cited by 270 · see citing works

Bystander elimination of antigen loss variants in established tumors

Spiotto, M. T., Rowley, D. A., & Schreiber, H. W. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260 · see citing works

Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.

Fridman, R., Giaccone, G., Kanemoto, T., Martin, G. R., Gazdar, A. F., & Mulshine, J. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6698 · Cited by 255 · see citing works

Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1

Sanz-Rodrı́guez, F., Hidalgo, A., & Teixidó, J. (2001) · Blood · doi:10.1182/blood.v97.2.346 · Cited by 253 · see citing works

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

Nefedova, Y., Landowski, T. H., & Dalton, W. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402924 · Cited by 248 · see citing works

Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer

Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K. E., Vaidya, A. P., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 247 · see citing works

Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation

Maeda, T., Kawane, T., & Horiuchi, N. (2003) · Endocrinology · doi:10.1210/en.2002-220682 · Cited by 230 · see citing works

Ras GTPases: integrins' friends or foes?

Kinbara, K., Goldfinger, L. E., Hansen, M. B., Chou, F.-L., & Ginsberg, M. H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1229 · Cited by 228 · see citing works

Increased β1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer

Yao, E. S., Zhang, H., Chen, Y., Lee, B., Chew, K., Moore, D. A., & Park, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2768 · Cited by 227 · see citing works

β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts

Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6390 · Cited by 220 · see citing works

β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 200 · see citing works

Quantitative model for multiple levels of drug resistance in clinical tumors.

Goldie, J. H., & Coldman, A. J. (1983) · PubMed · Cited by 191 · see citing works

Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma

Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190 · see citing works

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

Landowski, T. H., Olashaw, N., Agrawal, D., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206315 · Cited by 187 · see citing works

Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1

Wiedswang, G., Borgen, E., Kåresen, R., Qvist, H., Janbu, J., Kvalheim, G., Nesland, J. M., & Naume, B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0245 · Cited by 185 · see citing works

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403405 · Cited by 182 · see citing works

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

Cianfrocca, M. E., Kimmel, K. A., Gallo, J. M., Cardoso, T., Brown, M. M., Hudes, G. R., Lewis, N. L., Weiner, L. M., Lam, G. N., Brown, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603171 · Cited by 182 · see citing works

Galectin-1 Interacts with the α5β1 Fibronectin Receptor to Restrict Carcinoma Cell Growth via Induction of p21 and p27

Fischer, C., Ruderisch, H. S., Welzel, M., Wiedenmann, B. J., Sakai, T., André, S., Gabius, H., Khachigian, L. M., Detjen, K. M., & Rosewicz, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411580200 · Cited by 177 · see citing works

Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B. M., Williams, P. J., Mundy, G. R., & Yoneda, T. (2004) · Blood · doi:10.1182/blood-2004-01-0236 · Cited by 175 · see citing works

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Anderson, K. C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 166 · see citing works

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

Frassanito, M. A., Cusmai, A., Iodice, G., & Dammacco, F. (2001) · Blood · doi:10.1182/blood.v97.2.483 · Cited by 160 · see citing works

Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27 KIP1

Henriet, P., Zhong, Z.-D., Brooks, P. C., Weinberg, K. I., & DeClerck, Y. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170290997 · Cited by 157 · see citing works

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

McNeel, D. G., Eickhoff, J. C., Lee, F. T., King, D. M., Alberti, D. B., Thomas, J. P., Friedl, A., Kolesar, J., Marnocha, R., Volkman, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0262 · Cited by 156 · see citing works

β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury

Cordes, N., Seidler, J. F., Durzok, R., Geinitz, H., & Brakebusch, C. (2005) · Oncogene · doi:10.1038/sj.onc.1209164 · Cited by 155 · see citing works

Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis

Récher, C., Ysebaert, L., Beyne‐Rauzy, O., Mas, V. M., Ruidavets, J., Cariven, P., Demur, C., Payrastre, B., Laurent, G., & Racaud‐Sultan, C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3005 · Cited by 153 · see citing works

Breast Carcinoma–Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes

Hawsawi, N. M., Ghebeh, H., Hendrayani, S., Tulbah, A. M., Al-Eid, M., Al‐Tweigeri, T., Ajarim, D. S., Alaiya, A. A., Dermime, S., & Aboussekhra, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0192 · Cited by 147 · see citing works

Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

Mullamitha, S., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K. E., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146 · see citing works

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia

Cario, G., Stanulla, M., Fine, B. M., Teuffel, O., Neuhoff, N. V., Schrauder, A., Flohr, T., Schäfer, B. W., Bartram, C. R., Welte, K., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1552 · Cited by 146 · see citing works

Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse

Bidard, F., Vincent‐Salomon, A., Gomme, S., Nos, C., Rycke, Y. D., Thiery, J. P., Sigal‐Zafrani, B., Mignot, L., Sastre‐Garau, X., Pierga, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4749 · Cited by 142 · see citing works

Untitled work

(2003) · PubMed · Cited by 141 · see citing works

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J. S., Shain, K. H., Saporta, S., Boulware, D. C., Moscinski, L. C., Alsina, M., et al. (2003) · PubMed · Cited by 138 · see citing works

ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase

Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., MacKinnon, A. C., Haslett, C., & Sethi, T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401849 · Cited by 136 · see citing works

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padró, T., Kropff, M. H., Scheffold, C., Kröger, M., Mesters, R. M., Berdel, W. E., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2907 · Cited by 127 · see citing works

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma

Kirshner, J., Thulien, K. J., Martin, L. D., Debes-Marun, C. S., Reiman, T., Belch, A. R., & Pilarski, L. M. (2008) · Blood · doi:10.1182/blood-2008-02-142430 · Cited by 127 · see citing works

Development and characterization of a melphalan-resistant human multiple myeloma cell line.

Bellamy, W. T., Dalton, W. S., Gleason-Guzman, M. C., Grogan, T. M., & Trent, J. M. (1991) · PubMed · Cited by 125 · see citing works

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia

Flotho, C., Coustan‐Smith, E., Pei, D., Cheng, C., Song, G., Pui, C., Downing, J. R., & Campana, D. (2007) · Blood · doi:10.1182/blood-2007-01-068478 · Cited by 123 · see citing works

Integrin Inhibitors Reaching the Clinic

Stupp, R., & Rüegg, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8376 · Cited by 122 · see citing works

Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells

Denoyelle, C., Albanese, P., Uzan, G., Li, H., Vannier, J., Soria, J., & Soria, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00124-9 · Cited by 121 · see citing works

Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines

Shain, K. H., Landowski, T. H., & Dalton, W. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2544 · Cited by 120 · see citing works

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase

Schmidmaier, R., Baumann, P., Şimşek, M., Dayyani, F., Emmerich, B., & Meinhardt, G. (2004) · Blood · doi:10.1182/blood-2003-12-4218 · Cited by 118 · see citing works

Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1293 · Cited by 115 · see citing works

RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma

Azab, A. K., Azab, F., Blotta, S., Pitsillides, C. M., Thompson, B. D., Runnels, J. M., Roccaro, A. M., Ngo, H. T., Melhem, M. R., Sacco, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199281 · Cited by 111 · see citing works

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia

Brisco, J., Hughes, E., Neoh, S. H., Sykes, P. J., Bradstock, K. F., Enno, A., Szer, J., McCaul, K. A., & Morley, A. (1996) · Blood · doi:10.1182/blood.v87.12.5251.bloodjournal87125251 · Cited by 108 · see citing works

Reversal by Hyaluronidase of Adhesion-Dependent Multicellular Drug Resistance in Mammary Carcinoma Cells

Croix, B. S., Rak, J. W., Kapitain, S. J., Sheehan, C., Graham, C. H., & Kerbel, R. S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.18.1285 · Cited by 106 · see citing works

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas

Lwin, T., Hazlehurst, L., Dessureault, S., Lai, R. L., Bai, W., Sotomayor, E. M., Moscinski, L. C., Dalton, W. S., & Tao, J. (2007) · Blood · doi:10.1182/blood-2006-11-060350 · Cited by 104 · see citing works

Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia

Matsunaga, T., Fukai, F., Miura, S., Nakane, Y., Owaki, T., Kodama, H., Tanaka, M., Nagaya, T., Takimoto, R., Takayama, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405017 · Cited by 100 · see citing works

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2

Flotho, C., Coustan‐Smith, E., Pei, D., Iwamoto, S., Song, G., Cheng, C., Pui, C., Downing, J. R., & Campana, D. (2006) · Blood · doi:10.1182/blood-2006-01-0322 · Cited by 99 · see citing works

Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells

Hazlehurst, L., Argilagos, R. F., Emmons, M. F., Boulware, D. C., Beam, C. A., Sullivan, D. M., & Dalton, W. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3256 · Cited by 84 · see citing works

β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells

Hazlehurst, L., Argilagos, R. F., & Dalton, W. S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06435.x · Cited by 82 · see citing works

Integrins and Cytokines Activate Nuclear Transcription Factor-κB in Human Neutrophils

Kettritz, R., Choi, M., Rolle, S., Wellner, M., & Luft, F. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309778200 · Cited by 77 · see citing works

Integrin chains ??1 and ??v as prognostic factors in human metastatic melanoma

Nikkola, J., Vihinen, P., Vlaykova, T. I., Hahka‐Kemppinen, M., Heino, J., & Pyrhönen, S. O. (2004) · Melanoma Research · doi:10.1097/00008390-200402000-00005 · Cited by 76 · see citing works

Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow

Heiss, M. M., Simon, E. H., Beyer, B. C. M., Gruetzner, K. U., Tarabichi, A., Babic, R., Schildberg, F. W., & Allgayer, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.003 · Cited by 74 · see citing works

Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma

Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y., Kranz, D. M., Rowley, D. A., & Schreiber, H. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5324 · Cited by 73 · see citing works

Status of minimal residual disease testing in childhood haematological malignancies

Campana, D. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07350.x · Cited by 72 · see citing works

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

Schmidmaier, R., Baumann, P., Bumeder, I., Meinhardt, G., Straka, C., & Emmerich, B. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00902.x · Cited by 71 · see citing works

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

Becker, P. S., Kopecky, K. J., Wilks, A. N., Chien, S. S., Harlan, J. M., Willman, C. L., Petersdorf, S. H., Stirewalt, D. L., Papayannopoulou, T., & Appelbaum, F. R. (2008) · Blood · doi:10.1182/blood-2007-12-124818 · Cited by 69 · see citing works

Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives

Weitz‐Schmidt, G., Welzenbach, K., Dawson, J., & Kallen, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407951200 · Cited by 67 · see citing works

A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

Søndergaard, T. E., Pedersen, P. K., Andersen, T., Søe, K., Lund, T., Østergaard, B., Garnero, P., Delaissé, J., & Plesner, T. (2008) · Hematological Oncology · doi:10.1002/hon.869 · Cited by 62 · see citing works

Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP

Perez, L. E., Parquet, N., Shain, K. H., Nimmanapalli, R., Alsina, M., Anasetti, C., & Dalton, W. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1545 · Cited by 57 · see citing works

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Folgiero, V., Avetrani, P., Bon, G., Carlo, S. E. D., Fabi, A., Nisticò, C., Vici, P., Melucci, E., Buglioni, S., Perracchio, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001592 · Cited by 51 · see citing works

Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.

Hoyt, D. G., Rusnak, J. M., Mannix, R. J., Modzelewski, R. A., Johnson, C. S., & Lazo, J. S. (1996) · PubMed · Cited by 48 · see citing works

Addressing the Role of Cell Adhesion in Tumor Cell Dormancy

White, D. E., Rayment, J. H., & Muller, W. J. (2006) · Cell Cycle · doi:10.4161/cc.5.16.2993 · Cited by 43 · see citing works

Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

Tancred, T. M., Belch, A. R., Reiman, T., Pilarski, L. M., & Kirshner, J. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.952200 · Cited by 42 · see citing works

Expression of MAC‐1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis

Graf, M., Reif, S., Kroell, T., Hecht, K., Nuessler, V., & Schmetzer, H. M. (2006) · American Journal of Hematology · doi:10.1002/ajh.20526 · Cited by 41 · see citing works

Disruption of Fibronectin Binding to the α5β1 Integrin Stimulates the Expression of Cyclin-dependent Kinases and DNA Synthesis through Activation of Extracellular Signal-regulated Kinase

Gong, J., Ko, T. C., & Brattain, M. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1662 · Cited by 38 · see citing works

Involvement of p53 in α4β1 integrin-mediated resistance of B-CLL cells to fludarabine

de la Fuente, M. T., Casanova, B., Cantero, E., del Cerro, M. H., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.054 · Cited by 38 · see citing works

Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.

Oshita, F., Kameda, Y., 池原, 瑞., Tanaka, G., Yamada, K., Nomura, I., Noda, K., Shotsu, A., Fujita, A., Arai, H., et al. (2002) · PubMed · Cited by 37 · see citing works

Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

Bisping, G., Wenning, D., Kropff, M. H., Gustavus, D., Müller‐Tidow, C., Stelljes, M., Munzert, G. M., Hilberg, F., Roth, G. J., Štefanič, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1612 · Cited by 33 · see citing works

Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method

Hess, C. J., Denkers, F., Ossenkoppele, G. J., Waisfisz, Q., McElgunn, C. J., Eldering, E., Schouten, J. P., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403520 · Cited by 28 · see citing works

Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC‐7721 through preventing Skp2‐dependent degradation of p27 via PI3K pathway

Fu, Y., Fang, Z., Liang, Y., Zhu, X., Prins, B. P., Li, Z., Wang, L., Sun, L., Jin, J., Yang, Y., et al. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21323 · Cited by 26 · see citing works

Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival

Moshaver, B., van der Pol, M. A., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701593636 · Cited by 23 · see citing works

Minimal Residual Disease in Acute Myeloid Leukemia Is Predicted by an Apoptosis-Resistant Protein Profile at Diagnosis

van Stijn, A., Feller, N., Kok, A., van der Pol, M. A., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1973 · Cited by 23 · see citing works

Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma

Vuoristo, M., Vihinen, P., Vlaykova, T. I., Nylund, C., Heino, J., & Pyrhönen, S. O. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e328270b935 · Cited by 22 · see citing works

Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma.

Azab, A. K., Azab, F., Pitsillides, C. M., Ngo, H. T., Jia, X., Melhem, M. R., Runnels, J. M., Roccaro, A. M., Sacco, A., Burwick, N. R., et al. (2008) · Blood · doi:10.1182/blood.v112.11.1666.1666 · Cited by 8 · see citing works

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · see citing works

The biology and function of fibroblasts in cancer

Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · see citing works

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works

The causes and consequences of genetic heterogeneity in cancer evolution

Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262 · see citing works

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,003 · see citing works

Tumor microenvironment and therapeutic response

Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802 · see citing works

Macrophages and Therapeutic Resistance in Cancer

Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · see citing works

Clinical and therapeutic relevance of cancer-associated fibroblasts

Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230 · see citing works

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness

Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230 · see citing works

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Huang, R., & Zhou, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,231 · see citing works

Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review

Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,159 · see citing works

Microtubules and resistance to tubulin-binding agents

Kavallaris, M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2803 · Cited by 1,134 · see citing works

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009 · see citing works

Fibroblast heterogeneity in the cancer wound

Öhlund, D., Elyada, E., & Tuveson, D. A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 940 · see citing works

How the ageing microenvironment influences tumour progression

Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849 · see citing works

Effect of exosomal miRNA on cancer biology and clinical applications

Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800 · see citing works

Tumor microenvironment: Sanctuary of the devil

Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 776 · see citing works

Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth

Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774 · see citing works

Microenvironmental regulation of therapeutic response in cancer

Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 769 · see citing works

Exosome mediated communication within the tumor microenvironment

Milane, L. S., Singh, A., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.029 · Cited by 738 · see citing works

Carcinoma-associated fibroblasts: orchestrating the composition of malignancyPreprint

Gascard, P. D., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 745 · see citing works

Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies

Yoshida, G. J. (2015) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716 · see citing works

Mechanisms and insights into drug resistance in cancer

Zahreddine, H. A., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660 · see citing works

The Wnt Signaling Pathway in Cancer

Duchartre, Y., Kim, Y.-M., & Kahn, M. (2015) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 498 · see citing works

Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy

Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542 · see citing works

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 477 · see citing works

Genetic heterogeneity and cancer drug resistance

Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 451 · see citing works

Molecular aspects of cancer cell resistance to chemotherapy

Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 409 · see citing works

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

Konopleva, M. Y., & Jordan, C. T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0904 · Cited by 401 · see citing works

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer

Haibe, Y., Kreidieh, M., Hajj, H. E., Khalifeh, I. M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 410 · see citing works

Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Saatci, Ö., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, Ö., Banister, C. E., Sikirzhytski, V., Tokat, Ü. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 373 · see citing works

Nuclear export of proteins and drug resistance in cancer

Turner, J. G., Dawson, J. L., & Sullivan, D. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.016 · Cited by 353 · see citing works

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

Itatani, Y., Kawada, K., Yamamoto, T. S., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 352 · see citing works

Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer

Hu, Y.-B., Yan, C., Mu, L., Huang, K., Li, X.-L., Tao, D., Wu, Y.-Q., & Qin, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125625 · Cited by 328 · see citing works

Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins

Lovitt, C. J., Shelper, T., & Avery, V. M. (2018) · BMC Cancer · doi:10.1186/s12885-017-3953-6 · Cited by 339 · see citing works

Drug resistance in metastatic castration-resistant prostate cancer

Šeruga, B., Ocaña, A., & Tannock, I. F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 337 · see citing works

Focal adhesion signaling and therapy resistance in cancer

Eke, I., & Cordes, N. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 331 · see citing works

Tumor-Host Interactions: A Far-Reaching Relationship

McAllister, S. S., & Weinberg, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4257 · Cited by 326 · see citing works

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Kurtova, A. V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M. P., Sivina, M., Wierda, W. G., Estrov, Z. E., Keating, M. J., et al. (2009) · Blood · doi:10.1182/blood-2009-07-233718 · Cited by 319 · see citing works

Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review

Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.009 · Cited by 316 · see citing works

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

Vyas, D., Laput, G. P., & Vyas, A. K. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60114 · Cited by 309 · see citing works

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids

Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305 · see citing works

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299 · see citing works

Tumor microenvironment promotes breast cancer chemoresistance

Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04222-w · Cited by 287 · see citing works

Cytokines, Inflammation and Colon Cancer

Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 290 · see citing works

Fibroblast activation in cancer: when seed fertilizes soil

Kužet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 286 · see citing works

Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death

Castells, M., Thibault, B., Delord, J., & Couderc, B. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285 · see citing works

Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials

Hua, F., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 282 · see citing works

Advanced Cell Culture Techniques for Cancer Drug Discovery

Lovitt, C. J., Shelper, T., & Avery, V. M. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 280 · see citing works

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 276 · see citing works

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 267 · see citing works

Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells

Wang, J., Liu, X., Qiu, Y., Shi, Y. X., Cai, J., Wang, B., Wei, X., Ke, Q., Sui, X. Y., Wang, Y., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0554-z · Cited by 268 · see citing works

Microenvironment and tumor cell plasticity: An easy way out

Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 263 · see citing works

The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment

Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261 · see citing works

Pharmacodynamic Drug–Drug Interactions

Niu, J., Straubinger, R. M., & Mager, D. E. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1434 · Cited by 278 · see citing works

The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?

Azcárate-Peril, M. A., Sikes, M. L., & Bruno-Bárcena, J. M. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2011 · Cited by 252 · see citing works

The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy

Wu, C., Hsieh, C., & Wu, Y. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 235 · see citing works

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works

β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy

Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M. A., Shevchenko, A., Sandfort, V., & Cordes, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61350 · Cited by 220 · see citing works

Therapeutic strategies targeting cancer stem cells

Yoshida, G. J., & Saya, H. (2015) · Cancer Science · doi:10.1111/cas.12817 · Cited by 216 · see citing works

Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance

Duluc, C., Moatassim-Billah, S., Chalabi‐Dchar, M., Perraud, A., Samain, R., Breibach, F., Gayral, M., Cordelier, P., Delisle, M., Bousquet, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404346 · Cited by 218 · see citing works

Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance

Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213 · see citing works

Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance

Liu, J., Li, P., Wang, L., Li, M., Ge, Z., Noordam, L., Lieshout, R., Verstegen, M. M. A., Ma, B., Su, J., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.09.003 · Cited by 211 · see citing works

The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer

Savant, S. S., Sriramkumar, S., & O’Hagan, H. M. (2018) · Cancers · doi:10.3390/cancers10080251 · Cited by 211 · see citing works

Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures

Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02599-7 · Cited by 210 · see citing works

Integrin Signaling in Cancer Cell Survival and Chemoresistance

Aoudjit, F., & Vuori, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/283181 · Cited by 207 · see citing works

CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors

Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205 · see citing works

Exosomes in development, metastasis and drug resistance of breast cancer

Yu, D., Wu, Y., Shen, H., Lv, M., Chen, W., Zhang, X., Zhong, S., Tang, J., & Zhao, J. (2015) · Cancer Science · doi:10.1111/cas.12715 · Cited by 204 · see citing works

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation

Kim, S. M., Kwon, O.-J., Hong, Y. K., Kim, J. H., Solca, F., Ha, S., Soo, R. A., Christensen, J. G., Lee, J. H., & Cho, B. C. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0311 · Cited by 202 · see citing works

Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance

Hu, Y.-B., Yan, C., Mu, L., Mi, Y., Zhao, H., Hu, H., Li, X., Tao, D., Wu, Y.-Q., Gong, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0557-9 · Cited by 185 · see citing works

Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy

Duan, C.-W., Shi, J., Chen, J., Wang, B., Yu, Y.-H., Qin, X., Zhou, X.-C., Cai, Y.-J., Li, Z.-Q., Zhang, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.015 · Cited by 198 · see citing works

Targeting CAFs to overcome anticancer therapeutic resistance

Saw, P. E., Chen, J., & Song, E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 198 · see citing works

Therapy resistance mediated by exosomes

Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0970-x · Cited by 191 · see citing works

The Role of STAT3 in Non-Small Cell Lung Cancer

Harada, D., Takigawa, N., & Kiura, K. (2014) · Cancers · doi:10.3390/cancers6020708 · Cited by 192 · see citing works

A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications

Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 188 · see citing works

The anticancer effects of ferulic acid is associated with induction of cell cycle arrest and autophagy in cervical cancer cells

Gao, J., Yu, H., Guo, W., Kong, Y., Gu, L., Li, Q., Yang, S., Zhang, Y., & Wang, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0595-y · Cited by 188 · see citing works

Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells

Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187 · see citing works

Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development

Jo, Y., Choi, N., Kim, K., Koo, H., Choi, J. H., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 185 · see citing works

Desmoplasia and Chemoresistance in Pancreatic Cancer

Schober, M., Jesenofsky, R., Faissner, R., Weidenauer, C., Hagmann, W., Michl, P., Heuchel, R. L., Haas, S., & Löhr, M. J. (2014) · Cancers · doi:10.3390/cancers6042137 · Cited by 183 · see citing works

Cancer-Associated Fibroblasts Share Characteristics and Pro-tumorigenic Activity with Mesenchymal Stromal Cells

Borriello, L., Nakata, R., Sheard, M. A., Fernandez, G. E., Sposto, R., Malvar, J., Blavier, L., Shimada, H., Asgharzadeh, S., Seeger, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2586 · Cited by 138 · see citing works

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.

Bent, E. H., Gilbert, L. A., & Hemann, M. T. (2016) · Genes &amp; Development · doi:10.1101/gad.284851.116 · Cited by 179 · see citing works

Tumors on chips: oncology meets microfluidics

Włodkowic, D., & Cooper, J. M. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.08.016 · Cited by 179 · see citing works

Mesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice

Tsai, K., Yang, S., Lei, Y., Tsai, C., Chen, H., Hsu, C., Chen, L., Wang, H., Miller, S. A., Chiou, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.045 · Cited by 175 · see citing works

Application of Evolutionary Principles to Cancer Therapy

Enríquez‐Navas, P. M., Wojtkowiak, J. W., & Gatenby, R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1337 · Cited by 175 · see citing works

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

Abdi, J., Chen, G., & Chang, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1497 · Cited by 172 · see citing works

Microenvironment drug resistance in multiple myeloma: emerging new players

Marzo, L. D., Desantis, V., Solimando, A. G., Ruggieri, S., Annese, T., Nico, B., Fumarulo, R., Vacca, A., & Frassanito, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10849 · Cited by 173 · see citing works

Beyond matrix stiffness: targeting force-induced cancer drug resistance

Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 173 · see citing works

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 165 · see citing works

Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery

Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168 · see citing works

β1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

Carbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., & Aghi, M. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0011 · Cited by 163 · see citing works

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

Harney, A. S., Karagiannis, G. S., Pignatelli, J., Smith, B. D., Kadioglu, E., Wise, S., Hood, M. M., Kaufman, M. D., Leary, C. B., Lu, W.-P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0241 · Cited by 162 · see citing works

Cancer invasion and resistance: interconnected processes of disease progression and therapy failure

Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 155 · see citing works

Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

Lutzny‐Geier, G., Köcher, T., Schmidt‐Supprian, M., Rudelius, M., Klein‐Hitpaß, L., Finch, A. J., Dürig, J., Wagner, M. M., Haferlach, C., Kohlmann, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.003 · Cited by 156 · see citing works

Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target

Togo, S., Polanska, U. M., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 156 · see citing works

The Microenvironment of Lung Cancer and Therapeutic Implications

Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154 · see citing works

Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer

Silva, A. S., Kam, Y., Khin, Z. P., Minton, S. E., Gillies, R. J., & Gatenby, R. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2235 · Cited by 152 · see citing works

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

Bhat, A. A., Nisar, S., Maacha, S., Carneiro-Lobo, T., Akhtar, S., Siveen, K. S., Wani, N. A., Rizwan, A., Bagga, P., Singh, M. K., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01294-3 · Cited by 143 · see citing works

Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies

Augsburger, D., Nelson, P. J., Kalinski, T., Udelnow, A., Knösel, T., Hofstetter, M. M., Qin, J. W., Wang, Y., Gupta, A. S., Bonifatius, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20136 · Cited by 144 · see citing works

Research progress of evironment-mediated drug resistance contributed to minimal residual disease

Zhang, T. (2011)

The influence of the tumor microenvironment on drug response and drug resistance

Dalton, W. S. (2008) · Clinical Cancer Research · Cited by 3 · see citing works

Le microenvironnement tumoral et la résistance thérapeutique

Borriello, L., & DeClerck, Y. A. (2014) · médecine/sciences · doi:10.1051/medsci/20143004021 · Cited by 23 · see citing works

The tumor microenvironment is a dominant force in multidrug resistance

Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443 · see citing works

The mesenchymal tumor microenvironment

Cukierman, E., & Bassi, D. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20210 · Cited by 45 · see citing works